Your browser doesn't support javascript.
loading
Short chain fatty acids (SCFAs) improves TNBS-induced colitis in zebrafish.
Morales Fénero, Camila; Amaral, Mariana Abrantes; Xavier, Izabella Karina; Padovani, Barbara Nunes; Paredes, Lais Cavalieri; Takiishi, Tatiana; Lopes-Ferreira, Mônica; Lima, Carla; Colombo, Alicia; Saraiva Câmara, Niels Olsen.
Afiliação
  • Morales Fénero C; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Amaral MA; Department of Medicine, Nephrology Division, Federal University of São Paulo, Brazil.
  • Xavier IK; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Padovani BN; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Paredes LC; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Takiishi T; ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.
  • Lopes-Ferreira M; Center of Toxins, Immune Response and Cellular Signalling (CeTICS), Instituto Butantan, São Paulo, Brazil.
  • Lima C; Center of Toxins, Immune Response and Cellular Signalling (CeTICS), Instituto Butantan, São Paulo, Brazil.
  • Colombo A; Department of Pathologic Anatomy, Faculty of Medicine, University of Chile, Santiago, Chile.
  • Saraiva Câmara NO; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Curr Res Immunol ; 2: 142-154, 2021.
Article em En | MEDLINE | ID: mdl-35492385
The short-chain fatty acids (SCFAs) are metabolites originated from the fermentation of dietary fibers and amino acids produced by the bacteria of the intestinal microbiota. The most abundant SCFAs, acetate, propionate, and butyrate, have been proposed as a treatment for inflammatory bowel diseases (IBDs) due to their anti-inflammatory properties. This work aimed to analyze the effects of the treatment of three combined SCFAs in TNBS-induced intestinal inflammation in zebrafish larvae. Here, we demonstrated that SCFAs significantly increased the survival of TNBS-exposed larvae, preserved the intestinal endocytic function, reduced the expression of inflammatory cytokines and the intestinal recruitment of neutrophils caused by TNBS. However, SCFAs treatment did not appear to avoid TNBS-induced tissue damage in the intestinal wall and did not restore the number of mucus-producing goblet cells. Finally, exposure to TNBS induced dysbiosis of the microbiota with an increase in Betaproteobacteria and Actinobacteria, while the treatment with SCFAs maintained these population levels similar to control. Thus, we demonstrate that the treatment of three combined SCFAs presented anti-inflammatory properties previously seen in mammals, opening an opportunity to use zebrafish to explore the potential benefit of these and other metabolites to treat inflammation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Res Immunol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Res Immunol Ano de publicação: 2021 Tipo de documento: Article